SHERIDAN, WYOMING – November 10, 2024 – Akron Bio, a recognized leader in biomanufacturing, continues to expand its capabilities in the field of recombinant protein development and manufacturing. With decades of experience and an unwavering commitment to quality, Akron offers comprehensive services designed to meet the needs of clients across the biotechnology, pharmaceutical, and gene therapy industries. By combining cutting-edge technology, cGMP compliance, and a deep understanding of recombinant protein production, Akron is poised to deliver innovative solutions for complex biomanufacturing challenges.

SHERIDAN, WYOMING – November 10, 2024 – Akron Bio, a leader in biotechnology and biomanufacturing, has continued to elevate its commitment to quality and innovation with the introduction of its state-of-the-art cGMP (current Good Manufacturing Practice) facility. Located in Sheridan, Wyoming, this new facility is poised to meet the ever-growing demand for high-quality plasmid DNA production, a critical component in the development of gene therapies, vaccines, and other advanced biologics.
Akron Bio’s new facility has been meticulously designed to meet the highest regulatory standards, ensuring that every stage of its plasmid DNA production is held to the strictest quality and compliance measures. This advanced facility operates in full compliance with FDA 21 CFR Part 11 and Eudralex Vol. 4 Annex 11, ensuring that both ancillary materials and drug substances are manufactured to the highest cGMP standards.

SHERIDAN, WYOMING – November 10, 2024 – PSI Engineering, a leading provider of end-to-end pack line solutions, has announced its successful collaboration with Cardinal Health at-Home Solutions to revolutionize their outbound operations through advanced automation technology. This partnership has significantly enhanced Cardinal Health at-Home Solutions' distribution centers, enabling them to meet the growing demand for at-home medical supplies with greater efficiency and speed.
Cardinal Health at-Home Solutions, a division of Cardinal Health, plays a crucial role in providing essential medical supplies and equipment directly to approximately 5 million patients across the United States annually. These patients rely on Cardinal Health at-Home Solutions for critical products to manage chronic and serious medical conditions such as diabetes, incontinence, and more.

SHERIDAN, WYOMING – November 10, 2024 – Cardinal Health, a leading provider of healthcare products and services, today announced the launch of its Cardinal Health™ Rapid Influenza A & B Test Kit. This cost-effective, lateral flow test kit is designed to provide accurate and reliable detection of influenza A and B viruses in just 10 minutes, enabling healthcare professionals to make timely treatment decisions at the point of care.

“This test kit is an important tool for managing influenza outbreaks, especially during the flu season when rapid diagnosis is crucial for effective treatment and infection control.”

SHERIDAN, WYOMING – November 10, 2024 – In the intricate world of healthcare, ensuring the safety and efficacy of medical products is paramount. Cardinal Health, a leading healthcare services company, plays a critical role in this process through its specialized handling capabilities, including cold storage and chemical vaults. These capabilities safeguard the integrity of life-saving medicines and medical products, from the moment they leave the manufacturer to their arrival at healthcare facilities.

SHERIDAN, WYOMING – November 10, 2024 – Cardinal Health today issued a comprehensive overview of its Board of Directors’ engagement and governance related to the ongoing opioid crisis. The company underscored its commitment to addressing the epidemic’s impact and highlighted its multi-faceted approach to combating opioid misuse.
“Our Board of Directors and the entire Cardinal Health team care deeply about the devastation this epidemic of opioid misuse has caused families and communities,” the company stated. “We are proud of our work alongside others across the pharmaceutical supply chain to help address this complex national public health crisis.”   

SHERIDAN, WYOMING – November 10, 2024 – Cardinal Health (NYSE: CAH) today reported strong first quarter fiscal year 2025 results, with non-GAAP operating earnings increasing 12% to $625 million and non-GAAP diluted EPS increasing 9% to $1.88. The company also raised its fiscal year 2025 non-GAAP EPS guidance to $7.75 to $7.90, from $7.55 to $7.70.“We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,” said Jason Hollar, CEO of Cardinal Health. “The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year. Across the business, we remain focused on executing our plan to best serve our customers and create value for our shareholders.”

SHERIDAN, WYOMING – November 10, 2024 – Cardinal Health (NYSE: CAH) today announced the grand opening of its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business. The facility provides healthcare customers in Massachusetts, New Hampshire, Rhode Island, Maine, Vermont, and Eastern Connecticut with modernized operations and expanded capacity, as well as specialized handling capabilities for products with strict storage requirements, available early 2025. At nearly 317,000 square feet, the new facility has replaced the Cardinal Health Bedford, Massachusetts, distribution center with double the warehouse space and triple the capacity for product storage locations.

SHERIDAN, WYOMING – November 10, 2024 – SHERIDAN, WYOMING – November 10, 2024 – Heart attacks and cardiac arrests are serious heart-related emergencies that can be life-threatening. While the terms are often used interchangeably, they are distinct conditions with different causes and treatments.

Heart Attack: A 'Plumbing' Problem

A heart attack occurs when blood flow to the heart is severely restricted or completely blocked. This blockage, typically caused by plaque buildup in the coronary arteries, deprives the heart muscle of oxygen, leading to tissue damage.

"A heart attack is often referred to as a 'plumbing' problem, because blood flow to the heart is interrupted, causing heart tissue to die," explains Rachel Keever, M.D., Medical Executive, Health Systems Integration at Johnson & Johnson Innovative Medicine's Cardiovascular therapeutic area in the U.S.

Risk Factors for Heart Attack

SHERIDAN, WYOMING – November 10, 2024 – SHERIDAN, WYOMING – November 10, 2024 – Shockwave Medical, a Johnson & Johnson MedTech company and a global leader in circulatory restoration, announced positive 30-day results from its DISRUPT BTK II study. This post-market study evaluated the safety and effectiveness of the Shockwave Peripheral IVL System in treating calcified peripheral lesions below the knee (BTK), including patients with critical limb-threatening ischemia (CLTI).

Addressing Peripheral Artery Disease with IVL Technology

Peripheral artery disease (PAD) affects over 8 million people aged 40 and older in the United States. PAD can significantly impact quality of life and increase the risk of heart attack or stroke. CLTI, the most severe form of PAD, affects nearly 2 million U.S. patients and carries a high risk of amputation and mortality.